GYRE · NASDAQ · Biotechnology

Gyre Therapeutics (GYRE)

A majority-owned Beijing unit sells China's pirfenidone lung-fibrosis therapy while San Diego runs the antifibrotic pipeline.

$7.34
vs last close−0.15 (−2.00%)